Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.
Animals
Antineoplastic Agents, Immunological
/ pharmacology
CD28 Antigens
/ immunology
CD8-Positive T-Lymphocytes
/ drug effects
Cell Proliferation
/ physiology
Female
Humans
Lymphocyte Activation
Mice
Mice, Inbred C57BL
Neoplasms, Glandular and Epithelial
/ drug therapy
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Single-Cell Analysis
/ methods
Survival Rate
Transcriptome
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
29
10
2019
revised:
04
02
2020
accepted:
09
04
2020
pubmed:
17
4
2020
medline:
16
1
2021
entrez:
17
4
2020
Statut:
ppublish
Résumé
Although understanding of T-cell exhaustion is widely based on mouse models, its analysis in patients with cancer could provide clues indicating tumor sensitivity to immune checkpoint blockade (ICB). Data suggest a role for costimulatory pathways, particularly CD28, in exhausted T-cell responsiveness to PD-1/PD-L1 blockade. Here, we used single-cell transcriptomic, phenotypic, and functional approaches to dissect the relation between CD8
Identifiants
pubmed: 32295784
pii: 2326-6066.CIR-19-0855
doi: 10.1158/2326-6066.CIR-19-0855
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
CD28 Antigens
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
869-882Informations de copyright
©2020 American Association for Cancer Research.